Sante Atlantique
- Address
- lock Available on a paid plan
Digestive System Diseases
At Sante Atlantique, clinical research in digestive system diseases focuses on Crohn's disease and colorectal cancer, with studies aimed at improving treatment response and surgical outcomes.
- Testing whether a new therapeutic strategy can improve disease control in Crohn's disease after loss of response to current treatment.
- Evaluating ways to reduce complications in colorectal surgery by better assessing tissue perfusion during the operation.
- Supporting more effective care for patients with inflammatory bowel disease and cancer-related digestive conditions.
This area combines medical treatment research with surgical innovation, reflecting a strong interest in both long-term disease management and safer procedures.
Musculoskeletal Diseases
The anesthésie orthopédie department is also studying musculoskeletal diseases, especially acute low back pain, with research focused on better pain relief for recent lumbago.
- Assessing whether targeted anesthetic blocks can ease pain from muscle contractures in the first days after onset.
- Exploring improved symptom control for people with acute lumbar pain.
- Advancing practical approaches to short-term pain management in common back disorders.
This work is centered on improving comfort and recovery through more effective pain management strategies.
Neoplasms
Research in neoplasms at this site includes studies related to colorectal cancer, with a focus on making surgery safer and reducing postoperative complications.
- Studying whether intraoperative imaging can help surgeons better evaluate blood flow in bowel tissue.
- Aiming to lower the risk of anastomotic leakage after colorectal surgery.
- Supporting efforts to improve surgical outcomes for patients with cancer of the colon and rectum.
These trials reflect a strong interest in surgical innovation and in improving the safety of cancer treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sante Atlantique
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Vedolizumab Versus Adalimumab Dose Intensification in Crohn's Disease Patients with Secondary Loss of Response to Adalimumab | Centre Hospitalier Universitaire De Saint Etienne | Phase III | Recruiting | May 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2024-05-27 | 2024-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
